GlassScriptPhysician profile
Tim R Valko
NPI 1831129287
$1,256.55
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $284 · 2021: $274.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $165.10 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $149.81 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $146.70 | 2019-2020 | |
| Neuronetics, INC. | $132.75 | 2019-2020 | |
| Lundbeck LLC | $132.04 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $59.48 | 2019 | |
| Ironshore Pharmaceuticals INC. | $57.76 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $56.32 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.71 | 2019-2020 | |
| Neos Therapeutics, LP | $47.84 | 2019 | |
| Neurocrine Biosciences, INC. | $47.17 | 2019 | |
| Shire North American Group INC | $37.99 | 2019 | |
| Allergan, INC. | $37.84 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $34.54 | 2019 | |
| Jazz Pharmaceuticals INC. | $30.71 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27.16 | 2021 | |
| Indivior INC. | $14.66 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.56 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.41 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tim Valko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.